Recent translational research: Computational studies of breast cancer

Breast Cancer Research

Volumn 7, Issue 1, 2005, Pages 37-40

  Retsky, Michael ^a   Demicheli, Romano ^a   Hrushesky, William ^a   Speer, John ^a   Swartzendruber, Douglas ^a   Wardwell, Robert ^a  

^a PEPPERDINE UNIVERSITY   (United States)

Author keywords

Breast cancer; Computer models; Dormancy; Early detection; Exponential growth; Gompertzian growth; Risk

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; ARTIFICIAL NEURAL NETWORK; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CLINICAL STUDY; COMPUTER ANALYSIS; COMPUTER MODEL; COMPUTER PROGRAM; COMPUTER SYSTEM; CORRELATION ANALYSIS; EARLY DIAGNOSIS; FAMILY HISTORY; HUMAN; INDIVIDUALIZATION; INFORMATION PROCESSING; MATHEMATICAL MODEL; MATHEMATICS; METASTASIS POTENTIAL; PRACTICE GUIDELINE; PROGNOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; TUMOR GROWTH;

BREAST NEOPLASMS; CLINICAL TRIALS; COMPUTATIONAL BIOLOGY; DISEASE PROGRESSION; FEMALE; HUMANS; MODELS, THEORETICAL; PROGNOSIS;

EID: 13444282248     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr981     Document Type: Article

References (60)

1. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989, 81:1879-1886.
2. Tyrer J, Duffy SW, Cuzick J: A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004, 23:1111-1130.
3. Lisboa PJ: A review of evidence of health benefit from artificial neural networks in medical intervention. Neural Netw 2002, 15:11-39.
4. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001, 19:980-991.
5. Jerez-Aragones JM, Gomez-Ruiz JA, Ramos-Jimenez G, Munoz-Perez J, Alba-Conejo E: A combined neural network and decision trees model for prognosis of breast cancer relapse. Artif Intell Med 2003, 27:45-63.
6. Seker H, Odetayo MO, Petrovic D, Naguib RN: A fuzzy logic based-method for prognostic decision making in breast and prostate cancers. IEEE Trans Inf Technol Biomed 2003, 7:114-122.
7. Ripley RM, Harris AL, Tarassenko L: Non-linnear survival analysis using neural networks. Stat Med 2004, 23:825-842.
8. Biganzoli E, Boracchi P, Coradini D, Grazia Daidone M, Marubini E: Prognosis in node-negative primary breast cancer: a neural network analysis of risk profiles using routinely assessed factors. Ann Oncol 2003, 14:1484-1493.
9. Lisboa PJ, Wong H, Harris P, Swindell R: A Bayesian neural network approach for modelling censored data with an application to prognosis after surgery for breast cancer. Artif Intell Med 2003, 28:1-25.
10. Orbe J, Ferreira E, Nunez-Anton V: Comparing proportional hazards and accelerated failure time models for survival analysis. Stat Med 2002, 21:3493-3510.
11. Collins VP, Loeffler RK, Tivey H: Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 1956, 76:988-1000.
12. Coldman AJ, Goldie JH: Role of mathematical modeling in protocol formulation in cancer chemotherapy. Cancer Treat Rep 1985, 69:1041-1048.
13. Steel GG: Growth Kinetics of Tumours. Oxford: Clarendon Press; 1977.
14. Laird AK: Dynamics of tumor growth. Br J Cancer 1964, 18: 490-502.
15. Demicheli R, Terenziani M, Valagussa P, Moliterni A, Zambetti M, Bonadonna G: Local recurrences following mastectomy: support for the concept of tumor dormancy. J Natl Cancer Inst 1994, 86: 5-48.
16. Goodison S, Kawai K, Hihara J, Jiang P, Yang M, Urquidi V, Hoffman RM, Tarin D: Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res 2003, 9:3808-3814.
17. Chambers AF, Groom AC, MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572.
18. Stoll BA: Prolonged survival in breast cancer. In Prolonged Arrest of Cancer, volume 1. New York: John Wiley & Sons; 1982: 59-86.
19. Udagawa T, Fernandez A, Achilles EG, Folkman J, D'Amato RJ: Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 2002, 16:1361-1370.
20. Hart IR: Perspective: tumour spread - the problems of latency. J Pathol 1999, 187:91-94.
21. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC, Chambers AF: Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 2003, 82:199-206.
22. Klauber-DeMore N, Van Zee KJ, Linkov I, Borgen PI, Gerald WL: Biological behavior of human breast cancer micrometastases. Clin Cancer Res 2001, 7:2434-2439.
23. Meltzer A: Dormancy and breast cancer. J Surg Oncol 1990, 43:181-188.
24. Uhr JW, Scheuermann RH, Street NE, Vitetta ES: Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 1997, 3:505-509.
25. Kuznetsov VA, Knott GD: Modeling tumor regrowth and immunotherapy. Math Comp Modelling 2001, 33:1275-1287.
26. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L: Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response and postvascular dormancy. Cancer Res 1999, 59:4770-4775.
27. Fisher ER, Sass R, Fisher B: Pathologic findings from the National Adjuvant Project for Breast Cancers (protocol no. 4). Cancer 1984, Suppl:712-723.
28. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996, 14:2738-2746.
29. Baum M, Badwe RA: Does surgery influence the natural history of breast cancer? In Breast Cancer. Controversies in Management. Edited by Wise H, Johnson HJ. Armonk, NY: Futura; 1994:61-69.
30. Bedwinek J: Adjuvant irradiation for early breast cancer. An ongoing controversy. Cancer 1984, Suppl:729-739.
31. de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelenat H, Fourquet A: Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993, 341:1039-1043.
32. Veronesi U, Marubini E, Del Vecchio M, Manzari A, Andreola S, Greco M, Luini A, Merson M, Saccozzi R, Rilke F, et al.: Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 1995, 87:19-27.
33. Fortin A, Larochelle M, Laverdiere J, Lavertu S, Tremblay D: Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol 1999, 17:101-109.
34. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G: Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 1996, 41: 177-185.
35. Retsky M, Demicheli R, Hrushesky W: Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat 2001, 65:217-224.
36. Retsky M, Demicheli R, Hrushesky W: Breast cancer screening: controversies and future directions. Curr Opin Obstet Gynecol 2003, 15:1-8.
37. Demicheli R, Bonadonna G, Hrushesky WJ, Retsky MW, Valagussa P: Menopausal status dependence of early mortality reduction due to diagnosis of smaller breast cancers (T1 v T243): relevance to screening. J Clin Oncol 2004, 22:102-107.
38. Baines CJ: Mammography screening: are women really giving informed consent? J Natl Cancer Inst 2003, 95:1508-1511.
39. Cox B: Variation in the effectiveness of breast screening by year of follow-up. J Natl Cancer Inst Monogr 1997, 22: 9-72.
40. Maranto G: Should women in their 40s have mammograms? Sci Am 1996, 275:113.
41. NIH Consensus Development Panel: Consensus statement. J Natl Cancer Inst Monogr 1997, 22:vii.
42. Fletcher SW: Whither scientific deliberation in health policy recommendations? Alice in the Wonderland of breast-cancer screening. N Engl J Med. 1997, 336:1180-1183.
43. Norton L: Karnofsky Memorial Lecture: ignorato motu, ignoratur natura. In American Society of Clinical Oncology virtual meeting, 2004. www.asco.org
44. Hellman S, DeVita VT Jr: Principles of cancer biology: kinetics of cellular proliferation. In Cancer: Principles and Practices of Oncology. Edited by DeVita Jr, Hellman S, Rosenberg S. Philadelphia: Lippincott; 1982:13.
45. Cooper MR, Cooper MR: Principles of medical oncology. In American Cancer Society Textbook of Clinical Oncology. Edited by Holleb AI, Fink DJ, Murphy GP. Atlanta: American Cancer Society; 1991:47-68.
46. Prehn RT: The inhibition of tumor growth by tumor mass. Cancer Res 1991, 51:2-4.
47. Norton L: A Gompertzian model of human breast cancer growth. Cancer Res 1988, 48:7067-7071.
48. Guiot C, Degiorgis PG, Delsanto PP, Gabriele P, Deisboeck TS: Does tumor growth follow a 'universal law'? J Theor Biol 2003, 225:147-151.
49. Retsky M: Universal law of tumor growth [letter]. J Theor Biol 2004, 229:289.
50. Plevritis SK: A mathematical algorithm that computes breast cancer sizes and doubling times detected by screening. Math Biosci 2001, 171:155-178.
51. Retsky MW, Demicheli R, Swartzendruber DE, Bame PD, Wardwell RH, Bonadonna G, Speer JF, Valagussa P: Computer simulation of a breast cancer metastasis model. Breast Cancer Res Treat 1997, 45:193-202.
52. Demicheli R, Retsky MW, Swartzendruber DE, Bonadonna G: Proposal for a new model of breast cancer metastatic development. Ann Oncol 1997, 8:1075-1080.
53. Retsky M, Bonadonna G, Demicheli R, Folkman J, Hrushesky W, Valagussa P: Hypothesis: induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res 2004, 6: R372-R374.
54. Castiglione-Gertsch M, Gelber R, Goldhirsch A: Adjuvant systemic therapy: the issues of timing and sequence. Recent Results Cancer Res 1996, 140:201-213.
55. Frei E III, Richardson P, Avigan D, Bunnell C, Wheeler C, Elias A: The interval between courses of high dose chemotherapy with stem cell rescue: therapeutic hypothesis. Bone Marrow Transplant 1999, 24:939-945.
56. Cooke R: Dr. Folkman's War: Angiogenesis and the Struggle to Defeat Cancer. New York: Random House; 2000:328-350.
57. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878-1886.
58. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4:423-436.
59. Retsky M, Swartzendruber D, Wardwell R, Bame P: Computer model challenges breast cancer treatment strategy. Cancer Invest 1994, 12:559-567.
60. Clare SE, Nakhlis F, Panetta JC: Review: molecular biology of breast cancer metastasis: the use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer. Breast Cancer Res 2000, 2:430-435.